The interplay between muscle mass decline, obesity, and type 2 diabetes.

Abstract

The world's population is progressively becoming older, and age‑related conditions are a major public health concern. A worrying phenomenon worldwide is the increasing obesity among aging societies, which occurs in parallel with a higher prevalence of sarcopenia in older populations. As a result of the combination of these 2 states, new medical conditions, such as sarcopenic obesity, have recently become a public health concern. Data from the literature indicate a higher risk of metabolic syndrome, type 2 diabetes (T2D), and atherosclerosis among patients with sarcopenic obesity than the risk associated with simple obesity or sarcopenia alone. The mechanisms underlying sarcopenic obesity are multifactorial. There is an interplay between low‑grade inflammation, insulin resistance, hormonal changes, a sedentary lifestyle, eating habits, and aging. The aim of this review is to summarize the available data regarding the definition, epidemiology, and pathways that lead to sarcopenic obesity, as well as treatment strategies.